Breaking News, Collaborations & Alliances

BioVaxys Inks Deal with CDMO BioElpida

Includes clinical-grade bioproduction and aseptic packaging for ovarian cancer vaccine candidate BXV-0918A.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioVaxys Technology Corp. has signed a definitive exclusive bioproduction agreement with BioElpida S.A.S. of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys’ vaccine candidate for Stage III/Stage IV ovarian cancer.    BioVaxys and BioElpida executed a Term Sheet in February outlining the commercial relationship, with the definitive agreement focusing on the GMP facility build-out in Lyon, and technical aspects of the bioproduction proto...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters